Low Doses of Acetylsalicylic Acid Increase Risk of Gastrointestinal Bleeding in a Meta-Analysis

Clinical Gastroenterology and Hepatology

Volumn 9, Issue 9, 2011, Pages

  Lanas, Angel ^a   Wu, Ping ^b   Medin, Jennie ^c   Mills, Edward J ^b  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b UNIVERSITY OF OTTAWA   (Canada)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Anti inflammatory; Cardiovascular Disease; Side Effect; Therapy

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; LANSOPRAZOLE; OMEPRAZOLE; WARFARIN;

ARTICLE; BRAIN HEMORRHAGE; DRUG SAFETY; EVALUATION AND FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTENTION TO TREAT ANALYSIS; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; MORTALITY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SECONDARY PREVENTION;

EID: 80052026195     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.05.020     Document Type: Article

References (33)

1. Baigent C., Blackwell L., Collins R., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009, 373:1849-1860.
2. Calvin A.D., Aggarwal N.R., Murad M.H., et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 2009, 32:2300-2306.
3. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86. Antithrombotic Trialists' Collaboration.
4. Rothwell P.M., Fowkes F.G., Belch J.F., et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377:31-41.
5. Garcia Rodriguez L.A., Hernández-Díaz S., de Abajo F.J. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 2001, 52:563-571.
6. Bhatt D.L., Scheiman J., Abraham N.S., et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008, 52:1502-1517.
7. Wolff T., Miller T., Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009, 150:405-410.
8. García S., Rodríguez L.A. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med 2006, 4:22.
9. McQuaid K.R., Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006, 119:624-638.
10. Berger J.S., Krantz M.J., Kittelson J.M., et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009, 301:1909-1919.
11. Serebruany V.L., Malinin A.I., Ferguson J.J., et al. Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients. Fundam Clin Pharmacol 2008, 22:315-321.
12. Roston A., Muir K., Dube C., et al. Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drugs Healthc Patient Saf 2009, 1:47-71.
13. Meade M.O., Guyatt G.H., Cook R.J., et al. Agreement between alternative classifications of acute respiratory distress syndrome. Am J Respir Crit Care Med 2001, 163:490-493.
14. Yusuf S., Peto R., Lewis J., et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985, 27:335-371.
15. McAlister F.A., Straus S.E., Guyatt G.H., et al. Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. JAMA 2000, 283:2829-2836. Evidence-Based Medicine Working Group.
16. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
17. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
18. O'Regan C., Ghement I., Eyawo O., et al. Incorporating multiple interventions in meta-analysis: an evaluation of the mixed treatment comparison with the adjusted indirect comparison. Trials 2009, 10:86.
19. Chan F.K., Chung S.C., Suen B.Y., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001, 344:967-973.
20. Lai K.C., Lam S.K., Chu K.M., et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002, 346:2033-2038.
21. Bhatt D.L., Cryer B.L., Contant C.F., et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010, 363:1909-1917.
22. Vist G.E., Hagen K.B., Devereaux P.J., et al. Systematic review to determine whether participation in a trial influences outcome. BMJ 2005, 330:1175.
23. Sun X., Briel M., Walter S.D., et al. Is a subgroup effect believable?. Updating criteria to evaluate the credibility of subgroup analyses. BMJ 2010, 340:c117.
24. Bowry A.D., Brookhart M.A., Choudhry N.K. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. Am J Cardiol 2008, 101:960-966.
25. Haq S.A., Heitner J.F., Sacchi T.J., et al. Long-term effect of chronic oral anticoagulation with warfarin after acute myocardial infarction. Am J Med 2010, 123:250-258.
26. Smeeth L., Haines A., Ebrahim S. Numbers needed to treat derived from meta-analyses-sometimes informative, usually misleading. BMJ 1999, 318:1548-1551.
27. Montori V.M., Permanyer-Miralda G., Ferreira-González I., et al. Validity of composite end points in clinical trials. BMJ 2005, 330:594-596.
28. Lanas A. Non-steroidal anti-inflammatory drugs and gastrointestinal bleeding. Ital J Gastroenterol Hepatol 1999, 31(Suppl 1):S37-S42.
29. Lanas A. Cyclo-oxygenase-1/cyclo-oxygenase-2 non selective non-steroidal anti-inflammatory drugs: epidemiology of gastrointestinal events. Dig Liver Dis 2001, 33(Suppl 2):S29-S34.
30. Lanas A. Nonsteroidal anti-inflammatory drugs, low-dose aspirin, and potential ways of reducing the risk of complications. Eur J Gastroenterol Hepatol 2001, 13:623-626.
31. Lanas A., García-Rodríguez L.A., Arroyo M.T., et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007, 102:507-515.
32. Lanas A., Bajador E., Serrano P., et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000, 343:834-839.
33. Bucher H.C., Guyatt G.H., Griffith L.E., et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997, 50:683-691.